Market capitalization | $9.17m |
Enterprise Value | $9.06m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.54 |
P/S ratio (TTM) P/S ratio | 0.55 |
P/B ratio (TTM) P/B ratio | 0.75 |
Revenue growth (TTM) Revenue growth | 52.61% |
Revenue (TTM) Revenue | $16.72m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Precipio, Inc.:
1 Analyst has issued a forecast Precipio, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 17 17 |
53%
53%
|
|
Gross Profit | 5.87 5.87 |
145%
145%
|
|
EBITDA | -4.10 -4.10 |
56%
56%
|
EBIT (Operating Income) EBIT | -5.59 -5.59 |
49%
49%
|
Net Profit | -3.83 -3.83 |
65%
65%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. Its products include MX-ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HRM kits and ICP liquid biopsy testing. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
Head office | United States |
CEO | Ilan Danieli |
Employees | 57 |
Founded | 1997 |
Website | www.precipiodx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.